Logo Image
|Articles|January 2, 2013

BASF Extends Offer Period for Omega-3 Firm Pronova to Jan 18

Pronova BioPharma owns the patent to omega-3 cardiovascular drug Lovaza.

BASF (Frankfurt) has extended the deadline for its offer to acquire Pronova BioPharma (Lysaker, Norway), which owns the patent to omega-3 cardiovascular drug Lovaza, to January 18, 2013. BASF says it expects to close the offer in the first quarter of 2013 and that Pronova’s board of directors and management unanimously support BASF’s offer and are recommending it be accepted.

The extended deadline is for BASF to acquire any outstanding shares of Pronova. BASF says it so far has received acceptances for approximately 67.2% of shares.

Related to this article

View more
Omega-3 Supply, Not Price, Is the Real Threat
Omega-3 Supply, Not Price, Is the Real Threat
With Peru's anchovy fishery opening its 2026 season with its lowest quota in a decade, Matts Johansen argues that aquaculture's growing appetite for omega-3s, not just El Niño, is what should actually be keeping supplement brands up at night.
Read more